Avoid Ranbaxy Laboratories: Sandip Sabharwal

Jun 26, 2013, 06.24 PM IST

Sandip Sabharwal of Prabhudas Lilladher advises to avoid Ranbaxy Laboratories and focus on the companies which are actually doing well.

Like this story, share it with millions of investors on M3

Sandip Sabharwal of Prabhudas Lilladher advises to avoid Ranbaxy Laboratories and focus on the companies which are actually doing well.

Like this story, share it with millions of investors on M3

Avoid Ranbaxy Laboratories: Sandip Sabharwal

Sandip Sabharwal of Prabhudas Lilladher advises to avoid Ranbaxy Laboratories and focus on the companies which are actually doing well.

. Share . Email . Print . A+A-

Sandip Sabharwal of Prabhudas Lilladher told CNBC-TV18, " Ranbaxy Laboratories has turned into a stock where most investors including us have typically avoided the stock. What has been coming out of the company in terms of what the management says and what actually comes out later, there is a huge difference between the two."

"I think it is better to avoid this stock at any given price at this point of time till more clarity comes and focus on the companies which are actually doing well," he added.

Also Read: Adulterated drugs: SC dismisses PIL against Ranbaxy

Harmonis Hubungan